1. Home
  2. MBIO vs QNCX Comparison

MBIO vs QNCX Comparison

Compare MBIO & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.77

Market Cap

5.8M

Sector

Health Care

ML Signal

HOLD

Logo Quince Therapeutics Inc.

QNCX

Quince Therapeutics Inc.

HOLD

Current Price

$1.33

Market Cap

6.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBIO
QNCX
Founded
2015
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.8M
6.9M
IPO Year
2023
2019

Fundamental Metrics

Financial Performance
Metric
MBIO
QNCX
Price
$0.77
$1.33
Analyst Decision
Hold
Analyst Count
0
2
Target Price
N/A
N/A
AVG Volume (30 Days)
30.5K
63.5M
Earning Date
05-13-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
98.99
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$0.08
52 Week High
$7.00
$4.55

Technical Indicators

Market Signals
Indicator
MBIO
QNCX
Relative Strength Index (RSI) 49.51 73.92
Support Level $0.71 $0.10
Resistance Level $1.00 $1.47
Average True Range (ATR) 0.05 0.15
MACD 0.01 0.08
Stochastic Oscillator 82.92 86.11

Price Performance

Historical Comparison
MBIO
QNCX

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

About QNCX Quince Therapeutics Inc.

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

Share on Social Networks: